Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis. - Foong YC; Merlo D; Gresle M; Buzzard K; Horakova D; Havrdova EK; Kalincik T; Roos I; Hodgkinson S; Lechner-Scott J; Lugaresi A; Weinstock-Guttman B; et al. (Journal of neurology, neurosurgery, and psychiatry, 2025)